Thursday May 25th 2017

Archive for August, 2014

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance

Immune surveillance of the CNS is critical for preventing infections; however, there is no accepted experimental model to assess the risk of infection when utilizing disease-modifying agents. We tested two approved agents for patients with multiple sclerosis (MS), [Read More]

Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis

Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis

CONCLUSIONSDTI at 3T shows that the impact of diffuse corticospinal tracts disease on sensory‐motor disability is greatly mediated by focal lesions in MS. (Source: Journal of Neuroimaging) [Read More]

Jugular Venous Flow Abnormalities in Multiple Sclerosis Patients Compared to Normal Controls

Jugular Venous Flow Abnormalities in Multiple Sclerosis Patients Compared to Normal Controls

CONCLUSIONAfter categorizing the MS population into two groups based upon anatomical stenosis, as determined from an absolute quantification of IJV cross section, clear differences in IJV flow between the ST‐MS and HC samples became evident. Despite the unknown etiology [Read More]

 Page 1 of 99  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]